Abstracts Archive - Page 806 of 2425 - ACR Meeting Abstracts

Abstract Number: L13 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Philip J. Mease¹, Proton Rahman ², Alice B. Gottlieb ³, Elizabeth Hsia ⁴, Alexa Kollmeier ⁵, Xie Xu ⁶, Ramanand Subramanian ⁵, Prasheen Agarwal ⁵, Shihong Sheng ⁵, Bei Zhou ⁵, Désirée van der Heijde ⁷ and Iain McInnes ⁸, ¹Swedish Medical Center and University of Washington, Seattle, Washington, ²Memorial University of Newfoundland, Newfoundland, Canada, ³Icahn School of Medicine at Mt Sinai, NY, NY, New York, New York, ⁴Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, Pennsylvania, ⁵Janssen Research & Development, LLC, Spring House, Pennsylvania, ⁶Janssen Research & Development, LLC, Spring House, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…
Abstract Number: L14 • 2019 ACR/ARP Annual Meeting
Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebo-controlled Sub-study of OPAL Balance
Peter Nash¹, Laura Coates ², Philip J. Mease ³, Alan Kivitz ⁴, Dafna Gladman ⁵, Frank Behrens ⁶, James C Wei ⁷, Dona Fleishaker ⁸, Joseph Wu ⁸, Cunshan Wang ⁸, Ana Romero ⁹, Lara Fallon ¹⁰, Ming-Ann Hsu ⁸ and Keith Kanik ⁸, ¹Griffith University, Brisbane, Queensland, Australia, ²University of Oxford, Oxford, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, Washington, ⁴Altoona Center for Clinical Research, Duncansville, ⁵University of Toronto, Toronto, Canada, ⁶CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁷Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ⁸Pfizer Inc, Groton, Connecticut, ⁹Pfizer Inc, Barcelona, Spain, ¹⁰Pfizer Inc, Montreal, Canada
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of PsA. Tofacitinib monotherapy has not been previously studied in PsA. This sub-study of…
Abstract Number: L15 • 2019 ACR/ARP Annual Meeting
Efficacy, Safety, and Pharmacodynamic Effects of the Bruton’s Tyrosine Kinase Inhibitor, Fenebrutinib (GDC-0853), in Moderate to Severe Systemic Lupus Erythematosus: Results of a Phase 2 Randomized Controlled Trial
David Isenberg¹, Richard Furie ², Nicholas Jones ³, Pascal Guibord ⁴, Joshua Galanter ⁵, Chin Lee ³, Anna McGregor ³, Balazs Toth ³, Julie Rae ³, Olivia Hwang ³, Pedro Miranda ⁶, Viviane de Souza ⁷, Juan Jaller-Raad ⁸, Anna Maura Fernandes ⁹, Rodrigo Garcia Salinas ¹⁰, Leslie Chinn ³, Michael Townsend ¹¹, Alyssa Morimoto ³ and Katie Tuckwell ¹², ¹University College London, London, United Kingdom, ²Northwell Health, Great Neck, NY, ³Genentech, Inc., South San Francisco, California, ⁴Hoffmann-La Roche Limited, Mississauga, Canada, ⁵Genentech, Inc., SOUTH SAN FRANCISCO, ⁶Centro Estudios Reumatologicos, Santiago, Chile, ⁷Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil, ⁸Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia, ⁹Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil, ¹⁰Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, ¹¹Genentech, Inc., San Fransisco, ¹²Genentech, Inc., South San Francisco, CA
Background/Purpose: Fenebrutinib (GDC-0853, FEN) is an oral, non-covalent, and highly selective inhibitor of Bruton’s tyrosine kinase (BTK) in clinical development for autoimmune diseases. The efficacy,…
Abstract Number: L16 • 2019 ACR/ARP Annual Meeting
GLCCI1 Polymorphism Is Associated with Prednisone Response in Giant Cell Arteritis: A Multicenter Prospective Study
Samuel Deshayes¹, Venceslas Bourdin ², Christian Creveuil ³, Jonathan Boutemy ¹, Eric Liozon ⁴, Xavier Kyndt ⁵, Laurent Sailler ⁶, Grégory Pugnet ⁶, Hubert de Boysson ¹, Eric Hachulla ⁷, Marc André ⁸, Julie Magnant ⁹, Jacques Boddaert ¹⁰, Olivier Fain ¹¹, Arsène Mékinian ¹¹, Mohamed Hamidou ¹², Loïc Guillevin ¹³, Cédric Landron ¹⁴, Isabelle Marie ¹⁵, Yannick Chène ³, Laurent Becquemont ¹⁶, Céline Verstuyft ² and Boris Bienvenu ¹⁷, ¹Department of Internal Medicine, Caen University Hospital, Caen, France, ²INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Paris, France, ³Biomedical Reserch Unit, Caen University Hospital, Caen, France, ⁴Department of Internal Medicine and Clinical Immunology, Limoges University Hospital, Limoges, France, ⁵Department of Internal Medicine and Nephrology, Valenciennes Hospital, Valenciennes, France, ⁶Department of Internal Medicine, Toulouse University Hospital, Toulouse, France, ⁷Department of Internal Medicine and Clinical Immunology, Lille University Hospital, Lille, France, ⁸Department of Internal Medicine, Clermont-Ferrand University Hospital, Clermont-Ferrand, France, ⁹Department of Internal Medicine, Tours University Hospital, Tours, France, ¹⁰Department of Geriatrics, Pitié-Salpêtrière-Charles Foix University Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France, ¹¹Department of Internal Medicine, Saint Antoine University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, ¹²Department of Internal Medicine, Nantes University Hospital, Nantes, France, ¹³Department of Internal Medicine, Cochin University Hospital, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁴Department of Internal Medicine, Poitiers University Hospital, Poitiers, France, ¹⁵Department of Internal Medicine, Rouen University Hospital, Rouen, France, ¹⁶INSERM UMR_S1178, Medicine Faculty, CESP, Paris-Sud University, Le Kremlin Bicêtre, Le Kremblin Bicêtre, France, ¹⁷Department of Internal Medicine, Saint Joseph Hospital, Marseille, France
Background/Purpose: Giant cell arteritis (GCA) is the most common cause of primary vasculitis in adults. Corticosteroids are the cornerstone of the treatment. However, approximately 50%…
Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Eric Morand¹, Richard Furie ², Yoshiya Tanaka ³, Ian Bruce ⁴, Anca Askanase ⁵, Christophe Richez ⁶, Sang-Cheol Bae ⁷, Philip Brohawn ⁸, Lilia Pineda ⁹, Anna Berglind ¹⁰ and Raj Tummala ⁹, ¹Monash University, Melbourne, Victoria, Australia, ²Zucker School of Medicine at Hofstra/Northwell, New York, ³University of Occupational and Environmental Health, Kitakyushu, Japan, ⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ⁵Columbia University, New York, ⁶CHU de Bordeaux-GH Pellegrin, Bordeaux, France, ⁷Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁸Former employee of AstraZeneca, Gaithersburg, Maryland, ⁹AstraZeneca, Gaithersburg, Maryland, ¹⁰AstraZeneca, Gothenburg, Sweden
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…
Abstract Number: L18 • 2019 ACR/ARP Annual Meeting
A Human Recombinant Fusion Protein Targeting B Lymphocyte Stimulator (BlyS) and a Proliferation-Inducing Ligand (APRIL), Telitacicept (RC18), in Systemic Lupus Erythematosus (SLE): Results of a Phase 2b Study
Di Wu¹, Jing Li ², Dong Xu ², Wenxiang Wang ³, Lin Li ⁴, Jianmin Fang ³ and Fengchun Zhang ⁵, ¹Peking Union Medical College Hospital, Beijing, Beijing, China (People's Republic), ²Department of Rheumatology and Clinical Immunology Peking Union Medical College Hospital, Beijing, China (People's Republic), ³RemeGen, Ltd., Yantai, China (People's Republic), ⁴RemeGen, Ltd., Beijing, China (People's Republic), ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China (People's Republic)
Background/Purpose: Telitacicept, also named RC18, is a novel recombinant fusion protein constructed with the extracellular domain of the human transmembrane activator and calcium modulator and…
Abstract Number: L19 • 2019 ACR/ARP Annual Meeting
Ianalumab (VAY736), a Dual Mode of Action Biologic Combining BAFF Receptor Inhibition with B Cell Depletion, for Treatment of Primary Sjögren’s Syndrome: Results of an International Randomized, Placebo Controlled Dose Range Finding Study in 190 Patients
Simon Bowman¹, Robert Fox ², Thomas Dörner ³, Xavier Mariette ⁴, Athena Papas ⁵, Thomas Grader-Beck ⁶, Benjamin A. Fisher ⁷, Filipe Barcelos ⁸, Salvatore De Vita ⁹, Hendrik Schulze-Koops ¹⁰, Robert J. Moots ¹¹, Guido Junge ¹², Janice Woznicki ¹³, Monika Sopala ¹², Wen-Lin Luo ¹³ and Wolfgang Hueber ¹², ¹University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ²Scripps Memorial Hospital and Research Institute, La Jolla, California, ³Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ⁴Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ⁵Tufts School of Dental Medicine, Massachusetts, ⁶Johns Hopkins University, Baltimore, ⁷University Hospitals Birmingham NHS Foundation Trust, Birmingham Biomedical Research Centre, Birmingham, United Kingdom, ⁸Nova Medical School, Hospital Cuf Descobertas, Instituto Português de Reumatologia,, Lisbon, Portugal, ⁹Rheumatology Clinic, Udine University Hospital, Department of Medical Area, University of Udine, Udine, Italy, Udine, Italy, ¹⁰Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ¹¹Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ¹²Novartis Pharma AG, basel, Switzerland, ¹³Novartis Pharmaceuticals Corporation, New Jersey
Background/Purpose: Primary Sjogren’s syndrome (pSS) is a multi-organ autoimmune disease primarily affecting excretory glands and characterized by B-cell hyperactivity. No approved systemic treatments are available.…
Abstract Number: L20 • 2019 ACR/ARP Annual Meeting
A Head-to-Head Comparison of Ixekizumab and Adalimumab in Biologic-Naïve Patients with Active Psoriatic Arthritis: Efficacy and Safety Outcomes from a Randomized, Open-Label, Blinded Assessor Study Through 52 Weeks
Josef Smolen¹, Peter Nash ², Hasan Tahir ³, Hendrik Schulze-Koops ⁴, Lingnan Li ⁵, Maja Hojnik ⁶, Amanda Gellett ⁵, Soyi Liu-Leage ⁷, Sreekumar Pillai ⁷ and Philip J. Mease ⁸, ¹Medical University of Vienna, Vienna, Austria, ²Griffith University, Brisbane, Queensland, Australia, ³Royal Free London NHS Trust, London, United Kingdom, ⁴Department of Rheumatology/Clinical Immunology, Ludwig-Maximilians-University Munich, Munich, Germany, ⁵Eli Lilly and Company, Indianapolis, Indiana, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Swedish Medical Center and University of Washington, Seattle, Washington
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are available for treatment of PsA, but there are few direct comparisons of their efficacy and safety. Furthermore, efficacy of…
Abstract Number: L21 • 2019 ACR/ARP Annual Meeting
Secukinumab 150 mg Significantly Improved Signs and Symptoms of Non-radiographic Axial Spondyloarthritis: Results from a Phase 3 Double-blind, Randomized, Placebo-controlled Study
Atul Deodhar¹, Ricardo Blanco ², Eva Dokoupilova ³, Marleen van de Sande ⁴, Stephen Hall ⁵, Anna Wiksten ⁶, Brian Porter ⁷, Hanno Richards ⁶, Sibylle Haemmerle ⁶ and Jürgen Braun ⁸, ¹Oregon Health & Science University, Portland, OR, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³MEDICAL PLUS s.r.o., Uherske Hradiste; University of Veterinary and Pharmaceutical sciences, Faculty of Pharmacy, Department of Pharmaceutics, Brno, Czech Republic, ⁴Amsterdam Rheumatology and immunology Center, Department of Rheumatology and Clinical Immunology, Amsterdam UMC /University of Amsterdam, Amsterdam, Netherlands, ⁵Monash University, Melbourne, Australia, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: Non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) are considered part of the spectrum of axSpA. Patients (pts) are classified as nr-axSpA due to…
Abstract Number: L22 • 2019 ACR/ARP Annual Meeting
Tofacitinib for the Treatment of Polyarticular Course Juvenile Idiopathic Arthritis: Results of a Phase 3 Randomized, Double-blind, Placebo-controlled Withdrawal Study
Hermine Brunner¹, Olga Synoverska ², Tracy Ting ³, Carlos Abud Mendoza ², Alberto Spindler ², Yulia Vyzhga ², Katherine Marzan ³, Vladimir Keltsev ², Irit Tirosh ², Lisa Imundo ³, Rita Jerath ³, Daniel Kingsbury ³, Betul Sozeri ², Sheetal Vora ³, Sampath Prahalad ³, Elena Zholobova ², Yonatan Butbul Aviel ², Vyacheslav Chasnyk ², Melissa Lerman ³, Kabita Nanda ³, Heinrike Schmeling ³, Heather Tory ³, Yosef Uziel ², Diego Oscar Viola ², Holly Posner ⁴, Keith Kanik ⁵, Ann Wouters ⁴, Cheng Chang ⁵, Richard Zhang ⁴, Irina Lazariciu ⁶, Ming-Ann Hsu ⁵, Ricardo Suehiro ⁷, Alberto Martini ², Daniel J. Lovell ³ and Nicolino Ruperto ⁸, ¹PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ²PRINTO, Istituto Giannina Gaslini, Genova, Italy, ³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, ⁴Pfizer Inc, New York, New York, ⁵Pfizer Inc, Groton, Connecticut, ⁶IQVIA, Montreal, Quebec, Canada, ⁷Pfizer Inc, Collegeville, Pennsylvania, ⁸PRINTO, Istituto Giannina Gaslini, Genoa, Italy
Background/Purpose: Tofacitinib is an oral JAK inhibitor that is being investigated for JIA. Here we assess the efficacy and safety of tofacitinib in patients (pts)…
Abstract Number: 724 • 2019 ACR/ARP Annual Meeting
Biomechanical Properties of Skin for Assessment of Scleroderma: A Systemic Review
Peiyun Ni¹, Lilit Garibyan ² and Rox Anderson ², ¹Harvard-MIT Health Sciences and Technology, Harvard Medical School, Boston, MA, ²Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Skin involvement is one of the early features of scleroderma and an important predictor of internal organ involvement and mortality. Skin fibrosis alters the…
Abstract Number: 725 • 2019 ACR/ARP Annual Meeting
Amniotic Membrane Dressings Provide an Effective Treatment for Systemic Sclerosis Digital Ulcers
Tracy Frech¹, Jan Pierce ², Greg Stoddard ³, Constance McNeill ⁴, Mislav Radic ⁵ and Jo -Anna Reems ⁶, ¹Division of Rheumatology, University of Utah and Salt Lake VAMC, Salt Lake City, UT, ²University of Utah Regenerative Medicine, Salt Lake City, United Kingdom, ³University of Utah Study Design and Biostatics Core, Salt Lake City, UT, ⁴University of Utah Hospitals and Clinics, Salt Lake City, UT, ⁵University Hospital Split, Split, Croatia, ⁶University of Utah Regenerative Medicine, Salt Lake City, UT
Background/Purpose: Systemic sclerosis (SSc)-related digital ulcers are a major burden for patients. The purpose of this study was to assess the effectiveness of amnion membrane…
Abstract Number: 726 • 2019 ACR/ARP Annual Meeting
Digital Blood Perfusion Differences Between Black Africans and Caucasians with Systemic Sclerosis
Claudia Ickinger¹, Valerie Lambrecht ², Eustasius Musenge ³, Mohammed Tikly ¹, Maurizio Cutolo ⁴ and Vanessa Smith ⁵, ¹Division of Rheumatology, Chris Hani Baragwanath Academic Hospital, Faculty of Health Sciences, University of the Witwatersrand, Joahnnesburg, South Africa, ²Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ⁵Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium; Dept. of Internal Medicine, Ghent University, Ghent, Belgium; Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Ghent, Belgium, Gent, Belgium
Background/Purpose: Microvascular dysfunction is a prominent feature in SSc. Laser speckle contrast analysis (LASCA) has been shown to be a reliable tool to quantify skin…
Abstract Number: 727 • 2019 ACR/ARP Annual Meeting
Mortality and Morbidity in Scleroderma Renal Crisis: A Systematic Literature Review
Hyein Kim¹, Frédéric Lefebvre ², Sabrina Hoa ³ and Marie Hudson ⁴, ¹The University of British Columbia, Vancouver, Canada, ²University of Montreal, Montreal, Canada, ³University of Montreal, Montreal, QC, Canada, ⁴Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: The introduction of angiotensin converting enzyme (ACE) inhibitors in the early 1970s resulted in marked improvement in clinical outcomes of scleroderma renal crisis (SRC).Despite…
Abstract Number: 728 • 2019 ACR/ARP Annual Meeting
Nailfold Videocapillaroscopy Patterns and Digital Occlusive Arterial Disease on Laser Doppler Flowmetry Strongly Predicts the Diagnosis of Systemic Sclerosis and Other Connective Tissue Diseases
Yasser Radwan¹, Tina Gunderson ², Cynthia Crowson ³, David Liedl ⁴, Alicia Hinze ¹, Kenneth Warrington ⁴, Paul Wennberg ⁴ and Ashima Makol ¹, ¹Mayo Clinic Minnesota, rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic Rochester, rochester, MN
Background/Purpose: Vasculopathy is a key feature of systemic sclerosis (SSc), a chronic autoimmune disease associated with widespread fibrosis and internal organ dysfunction. While structural abnormalities…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].